Alfasigma to buy Galapagos’ JAK drug for up to €170m

Galapagos has signed a deal to jettison its troubled JAK inhibitor drug Jyseleca, agreeing to sell the rights to the rheumatoid arthritis and ulcerative colitis therapy to Italy’s Alfasigma SpA in a deal valued at up to €170 million plus royalties.